Skip to Content
Search Menu

LBA20: Sacituzumab Govitecan Significantly Prolongs PFS versus Chemotherapy in Advanced Triple-Negative Breast Cancer

Results from a late-breaking abstract presented at ESMO 2025 suggest that sacituzumab govitecan may establish a new standard of care for patients with advanced triple-negative breast cancer (TNBC).

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Related

Sustained efficacy and quality of life with darolutamide + ADT in mHSPC patients of all ages

/ Jan Andreasen
ESMO25Prostate cancer

RNA Expression Profiles May Guide Future Targeted Therapy in Urothelial Cancer

/ Jan Andreasen
Bladder cancerESMO25
Peeter Karihtala

The Clinical Value of Immuno-Oncological Treatments in Early Breast Cancer

/ Peeter Karihtala
Breast cancerOnkologiapäivät 2025 Play the Video 09:38
Katharina Leuchte

ESMO 2025: High-Intensity Interval Training Promotes Immune Responses in mNSCLC Patients

/ Katharina Leuchte
ESMO25Lung cancer Play the Video 05:43

Combination Therapy with Enzalutamide and Radium-223 in mCRPC: Insights from the REASSURE Study

/ Igle Jan de Jong / Jan Andreasen
ESMO25
John Crown

ESMO 2025: Ribociclib + NSAI Reduced the Risk of Invasive and Distant Recurrence of HR+/HER2−Early Breast Cancer

/ John Crown
Breast cancerESMO25NBCN Play the Video 03:24
Charles Geyer

ESMO 2025: Paradigm Shift in Breast Cancer Treatment

/ Charles E Geyer Jr.
Breast cancerESMO25NBCN Play the Video 05:53
Jakob Lauritsen

ESMO 2025: Interesting New Data on the Treatment of Bladder Cancer

/ Jakob Lauritsen
Bladder cancerESMO25 Play the Video 03:47
Hildur Helgadottir

ESMO 2025: Superior Outcomes With Reduced NIVO+IPI Dose in Advanced Melanoma

/ Hildur Helgadottir
ESMO25Melanoma Play the Video 05:27
Back to top